Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
INBRAIN has demonstrated the world’s first human use of a graphene-based BCI during brain tumor resection, showing high precision in distinguishing healthy from cancerous tissue. Ongoing clinical trials are evaluating safety and performance in neurological indications such as Parkinson's disease, epilepsy, stroke rehabilitation, and neurosurgical applications. The company’s BCI-Tx platform has shown superior signal fidelity versus traditional materials/devices in preclinical studies; early clinical results are promising but full efficacy data is pending.[3][6]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on INBRAIN Neuroelectronics.